Bill Haney, Dragonfly CEO (Getty Images)

Bris­tol My­ers bets $475M cash on a block­buster shot at break­ing the mold in im­muno-on­col­o­gy — with a po­ten­tial IL-12 game-chang­er

In the on­col­o­gy R&D world, IL-12 has a rep some­thing akin to ni­tro­glyc­er­ine in old Hol­ly­wood movies. It’s in­cred­i­bly pow­er­ful, but any false move and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.